# Liver Transplantation With ADV-TK Gene Therapy Improves Survival in Patients With Advanced Hepatocellular Carcinoma

> **NCT00300521** · PHASE2 · COMPLETED · sponsor: **Beijing Chao Yang Hospital** · enrollment: 40 (—)

## Conditions studied

- Hepatocellular Carcinoma
- Liver Transplantation

## Interventions

- **GENETIC:** ADV-TK (adenovirus-thymidine kinase enzyme) gene therapy

## Key facts

- **NCT ID:** NCT00300521
- **Lead sponsor:** Beijing Chao Yang Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-09
- **Primary completion:** —
- **Final completion:** 2005-11
- **Target enrollment:** 40 (—)
- **Last updated:** 2006-03-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00300521

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00300521, "Liver Transplantation With ADV-TK Gene Therapy Improves Survival in Patients With Advanced Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00300521. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*